格隆汇4月23日丨康方生物(09926.HK)发布公告,全球首创双特异性抗体新药依达方®(依沃西,PD-1/VEGF)联合化疗对比替雷利珠单抗联合化疗一线治疗晚期鳞状非小细胞肺癌(sq-NSCLC)的III期头对头临床试验(AK112-306/HARMONi-6),经独立数据监察委员会(IDMC)评估,期中分析显示强阳性结果:达到无进展生存期(PFS)的主要研究终点,具有统计学显著意义和重大临床...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.